Abstract 4096
Background
CAPRI, a randomized phase III trial comparing: an intervention combining Nurse Navigators (NNs) and a mobile application vs. Standard of care in cancer patients treated with oral anticancer agents was initiated in 2016 at Gustave Roussy (Villejuif, France). NNs provide regular telephone follow-ups to manage patients’ symptoms and assess toxicities, adherence to treatment and supportive care needs. Patients have access to a mobile application to record tracking data, contact NNs via secure messaging, view therapy and side effect information or store documents. Patient can contact the NNs on a dedicated phone line or by email/secure messaging
Methods
The present analysis involves 3 main data sources: - A questionnaire sent to patients after using for 5 months the CAPRI intervention in order to assess their experience, - Interviews conducted with patients to obtain their feedback of the intervention, - Data extraction from the application and NNs’ interventions over a 24-month period.
Results
Overall, 166 patients (83%) filled the questionnaire. Fifteen interviews were conducted. Patients’ experience with CAPRI intervention is summarized in the table below.Table: CN12
Items | % of patients strongly agree or agree |
---|---|
CAPRI intervention is useful | 96 |
Communicating with the NNs is a reassuring experience | 98 |
CAPRI intervention helps me to better manage my treatment | 79 |
CAPRI intervention is helpful in managing the side effects of my treatment | 87 |
CAPRI intervention helps me to become involved in my treatment | 81 |
CAPRI intervention responds to my expectations and needs for care | 90 |
I am satisfied with the responses from the NNs | 91 |
CAPRI intervention is overly constraining | 9 |
The open-ended comments on the questionnaires and interviews with patients highlighted the importance of listening, having a contact person who is easily reachable, available and empathetic. Concerning the use of the mobile application, 53% of patients reported having tried to connect and only 38% reported monitoring data at least once. By focusing on patient-NNs communication during the study period (817 requests), most contacts are performed by phone (78%) or e-mail (18%) but very few by secure messaging (4%).
Conclusions
Patients’ experience about the intervention was strongly positive. However, the mobile application is poorly used, suggesting that from the patients’ perspective, the presence of NNs is the key of the intervention.
Clinical trial identification
2016-A00254-47.
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
Fondation Philanthropia - Lombard Odier, Agence Nationale de la Recherche IHU-MMO, ARS Ile de France, Novartis, AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract